Iovance shareholders approve all proposals including equity plan increases at 2024 annual meeting

IOVANCE BIOTHERAPEUTICS, INC.

All seven director nominees elected; General McPeak did not stand for re-election, no disagreement.
Advisory vote on executive compensation passed with 173.75M for vs 10.03M against.
Ratification of Ernst & Young as auditor approved overwhelmingly (223.63M for).
Amendment to 2018 equity plan to increase authorized shares from 29.7M to 36.7M approved (177.46M for).
Amendment to 2020 ESPP to increase shares from 1.4M to 1.9M approved (182.04M for).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.